Abstract
Adoptive cell therapies (ACTs) using tumor-reactive T cells have shown clinical benefit and potential for cancer treatment. While the majority of the current ACT are focused on using CD8 + cytotoxic T lymphocytes (CTL), others have shown that the presence of tumor-reactive CD4 + T helper (Th) cells can greatly enhance the anti-tumor activity of CD8 + CTL. However, difficulties in obtaining adequate numbers of CD4 + Th cells through in vitro expansion can limit the application of CD4 Th cells in ACT. This study aims to optimize the culture conditions for mouse CD4 T cells to provide basic information for animal studies of ACT using CD4 T cells. Taking advantage of the antigen-specificity of CD4 + Th cells from OT-II transgenic mice, we examined different methodologies for generating antigen-specific CD4 + Th1 cells in vitro. We found that cells grown in complete advanced-DMEM/F12 medium supplemented with low-dose IL-2 and IL-7 induced substantial cell expansion. These Th cells were Th1-like, as they expressed multiple Th1-cytokines and exhibited antigen-specific cytotoxicity. In addition co-transfer of these CD4 + Th1-like cells with CD8 + CTL significantly enhanced tumor regression, leading to complete cure in 80% of mice bearing established B16-OVA. These observations indicate that the CD4 + Th1-like cells generated using the method we optimized are functionally active to eliminate their target cells, and can also assist CD8 + CTL to enhance tumor regression. The findings of this study provide valuable data for further research into in vitro expansion of CD4 + Th1-like cells, with potential applications to cancer treatment involving ACT.
Cite
CITATION STYLE
Li, K., Baird, M., Yang, J., Jackson, C., Ronchese, F., & Young, S. (2016). Conditions for the generation of cytotoxic CD4 + Th cells that enhance CD8 + CTL-mediated tumor regression. Clinical and Translational Immunology, 5(8). https://doi.org/10.1038/cti.2016.46
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.